Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1978 Sep;62(3):710–712. doi: 10.1172/JCI109179

Correlation of adenosine deaminase activity with cell surface markers in acute lymphoblastic leukemia.

J F Smyth, D G Poplack, B J Holiman, B G Leventhal, G Yarbro
PMCID: PMC371818  PMID: 308513

Abstract

Adenosine deaminase (ADA) activity has been measured in the lymphoblasts of 23 untreated patients with acute lymphoblastic leukemia and related to the presence or absence of immunologic cell surface markers. The mean ADA activity in the acute lymphoblastic leukemia population as a whole was increased fourfold over that in normal lymphocytes. 9 of the 23 patients were classified as thymus-derived (T-) cell acute lymphoblastic leukemia on the basis of erythrocyte rosette positivity; the remaining 14 patients had null-cell leukemia. The mean ADA activity (ADA U/mg protein) of T-cell lymphoblasts (102 U) was 3 times higher than the mean of null lymphoblasts (30 U). This difference is statistically significant (P less than 0.02). Measurement of ADA activity offers a biochemical method of distinguishing between immunological subtypes of lymphoblasts which may be of prognostic and therapeutic value.

Full text

PDF
710

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bowles C. A., White G. S., Lucas D. Rosette formation by canine peripheral blood lymphocytes. J Immunol. 1975 Jan;114(1 Pt 2):399–402. [PubMed] [Google Scholar]
  2. Coleman M. S., Hutton J. J. Terminal deoxynucleotidyl transferase and adenosine deaminase in human lymphoblastoid cell lines. Exp Cell Res. 1975 Sep;94(2):440–442. doi: 10.1016/0014-4827(75)90512-1. [DOI] [PubMed] [Google Scholar]
  3. Dissing J., Knudsen B. Adenosine-deaminase deficiency and combined immunodeficiency syndrome. Lancet. 1972 Dec 16;2(7790):1316–1316. doi: 10.1016/s0140-6736(72)92692-x. [DOI] [PubMed] [Google Scholar]
  4. Giblett E. R., Anderson J. E., Cohen F., Pollara B., Meuwissen H. J. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet. 1972 Nov 18;2(7786):1067–1069. doi: 10.1016/s0140-6736(72)92345-8. [DOI] [PubMed] [Google Scholar]
  5. HALL J. G. Adenosine deaminase activity in lymphoid cells during antibody production. Aust J Exp Biol Med Sci. 1963 Feb;41:93–97. doi: 10.1038/icb.1963.8. [DOI] [PubMed] [Google Scholar]
  6. Hovi T., Smyth J. F., Allison A. C., Williams S. C. Role of adenosine deaminase in lymphocyte proliferation. Clin Exp Immunol. 1976 Mar;23(3):395–403. [PMC free article] [PubMed] [Google Scholar]
  7. Humphrey G. B., Lankford J. Acute leukemia: the use of surface markers in classification. Semin Oncol. 1976 Sep;3(3):243–251. [PubMed] [Google Scholar]
  8. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  9. Meier J., Coleman M. S., Hutton J. J. Adenosine deaminase activity in peripheral blood cells of patients with haematological malignancies. Br J Cancer. 1976 Mar;33(3):312–319. doi: 10.1038/bjc.1976.45. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Meuwissen H. J., Pollara B., Pickering R. J. Combined immunodeficiency disease associated with adenosine deaminase deficiency. Report on a workshop held in Albany, New York, October 1, 1973. J Pediatr. 1975 Feb;86(2):169–181. doi: 10.1016/s0022-3476(75)80463-x. [DOI] [PubMed] [Google Scholar]
  11. Parkman R., Gelfand E. W., Rosen F. S., Sanderson A., Hirschhorn R. Severe combined immunodeficiency and adenosine deaminase deficiency. N Engl J Med. 1975 Apr 3;292(14):714–719. doi: 10.1056/NEJM197504032921402. [DOI] [PubMed] [Google Scholar]
  12. Pincus S., Bianco C., Nussenzweig V. Increased proportion of complement-receptor lymphocytes in the peripheral blood of patients with chronic lymphocytic leukemia. Blood. 1972 Sep;40(3):303–310. [PubMed] [Google Scholar]
  13. Scholar E. M., Calabresi P. Identification of the enzymatic pathways of nucleotide metabolism in human lymphocytes and leukemia cells. Cancer Res. 1973 Jan;33(1):94–103. [PubMed] [Google Scholar]
  14. Simone J. V., Aur R. J., Hustu H. O., Verzosa M., Pinkel D. Combined modality therapy of acute lymphocytic leukemia. Cancer. 1975 Jan;35(1):25–35. doi: 10.1002/1097-0142(197501)35:1<25::aid-cncr2820350105>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  15. Smyth J. F., Harrap K. R. Adenosine deaminase activity in leukaemia. Br J Cancer. 1975 May;31(5):544–549. doi: 10.1038/bjc.1975.95. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Smyth J. F., Young R. C., Young D. M. In vivo toxicity to lymphoid tissue by 2'-deoxycoformycin. Cancer Chemother Pharmacol. 1978;1(1):49–51. doi: 10.1007/BF00253146. [DOI] [PubMed] [Google Scholar]
  17. Tsukimoto I., Wong K. Y., Lampkin B. C. Surface markers and prognostic factors in acute lymphoblastic leukemia. N Engl J Med. 1976 Jan 29;294(5):245–248. doi: 10.1056/NEJM197601292940503. [DOI] [PubMed] [Google Scholar]
  18. Tung R., Silber R., Quagliata F., Conklyn M., Gottesman J., Hirschhorn R. Adenosine deaminase activity in chronic lymphocytic leukemia. Relationship to B- and T-cell subpopulations. J Clin Invest. 1976 Mar;57(3):756–761. doi: 10.1172/JCI108334. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Weiner M. S., Bianco C., Nussenzweig V. Enhanced binding of neuraminidase-treated sheep erythrocytes to human T lymphocytes. Blood. 1973 Dec;42(6):939–946. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES